Dysmobility Syndrome
Conditions
Interventions
Experimental group:Migu capsules combined with denosumab
Sponsors
Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
Eligibility
Sex/Gender
All
Age
60 Years to 90 Years
Inclusion criteria
Inclusion criteria: 1. Aged 60-90 years; 2. Meet the diagnosis of "osteoporotic-type" Dysmobility Syndrome: must meet criterion ?, and any two of criteria ?????: ? Osteoporosis: DXA measurement showing total T value = -2.5 at the lumbar spine, femoral neck, or proximal femur. ? History of falls: At least one fall in the past year. ? Slow gait speed: Gait speed 30% for males, > 40% for females. 3. Capability of performing basic daily activities independently or with the assistance of others and assistive devices. 4. Those who voluntarily participated in this study and signed informed consent.
Exclusion criteria
Exclusion criteria: 1.Not suitable for injection of denosumab in cases of unhealed dental or oral surgical wounds, hypocalcemia, or allergy to denosumab. 2.Allergic to Migu capsules. 3.Dominant neurological disorders (such as stroke and peripheral neuropathy), joint diseases (such as osteoarthritis), and vascular diseases (such as peripheral vascular disease) leading to varying degrees of functional impairment of the musculoskeletal system. 4.Limb disabilities (missing limbs or paralysis, deformities) leading to varying degrees of functional impairment of the musculoskeletal system. 5.Presence of spinal bone lesions such as spinal tuberculosis, spinal tumors, spinal cord tumors, detected by imaging examinations. 6.Patients with severe metabolic bone diseases such as primary hyperparathyroidism, hyperthyroidism, etc. 7. Patients with serious cardiovascular, cerebrovascular, liver, kidney, hematopoietic, digestive system and other diseases, or cognitive impairment and mental illness. 8.Unwilling to participate in this trial. 9.Other situations that the researcher considers unsuitable to participate in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Fall;Fracture;Bone mineral density;Grip strength; | — |
Secondary
| Measure | Time frame |
|---|---|
| Gait speed;Body composition analysis;5-time Chair Standing Test;Calf circumference;ADL;IADL;Movement information;SF36 Quality of Life Scale;Deficiency syndrome scale;Fracture risk;MNA-SF;Biochemical bone markers; | — |
Countries
China
Contacts
Public ContactYongfang Zhao
Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
Outcome results
None listed